Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients

Detalhes bibliográficos
Autor(a) principal: Monteiro,Camila Ribeiro de Arruda
Data de Publicação: 2019
Outros Autores: Schoueri,Jean Henri Maselli, Cardial,Debora Terra, Linhares,Lívia de Castro, Turke,Karine Corcione, Steuer,Lia Vineyard, Menezes,Levy Werneck de Almeida, Argani,Igor Luiz, Sette,Claudia, Cubero,Daniel de Iracema Gomes, Giglio,Auro del
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000500611
Resumo: SUMMARY INTRODUCTION: Drug interaction is an important cause of global morbidity. It is of particular importance in cancer patients since they are often in use of polypharmacy, related to interactions between the drugs and the chemotherapeutics used. OBJECTIVE: To evaluate the drug interaction between chemotherapy and other drugs in cancer patients. METHODS: a cross-sectional study carried out in the outpatient oncology department of a public tertiary hospital. Two hundred thirty-five patients were included, and the drugs they were using were identified. Using the MedScape and Epocrates database, we evaluated the interactions between medications and chemotherapy by defining their frequency and dividing their severity from interaction into mild, close monitoring necessity and severe. RESULTS: 161 patients had some drug interaction. We identified 9 types of mild interactions, 23 types of interactions with close monitoring necessity, and 2 types of serious interactions. The most frequent interactions were between fluorouracil and leucovorin (32 cases) and cyclophosphamide and doxorubicin (19 cases). Serious interactions were between aspirin and pemetrexed; and leucovorin and Bactrim. CONCLUSION: In the present study, drug interactions were frequent, including serious interactions with a potential increase in morbidity and mortality. Thus, it is necessary for oncologists to draw up a therapeutic plan considering potential interactions between prescribed chemotherapy and current medications in use by patients.
id AMB-1_46158c7fd7c15dbd1cb2bebfbae17d3a
oai_identifier_str oai:scielo:S0104-42302019000500611
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patientsDrug interactionsAntineoplastic agents/adverse effectsMedical oncologySUMMARY INTRODUCTION: Drug interaction is an important cause of global morbidity. It is of particular importance in cancer patients since they are often in use of polypharmacy, related to interactions between the drugs and the chemotherapeutics used. OBJECTIVE: To evaluate the drug interaction between chemotherapy and other drugs in cancer patients. METHODS: a cross-sectional study carried out in the outpatient oncology department of a public tertiary hospital. Two hundred thirty-five patients were included, and the drugs they were using were identified. Using the MedScape and Epocrates database, we evaluated the interactions between medications and chemotherapy by defining their frequency and dividing their severity from interaction into mild, close monitoring necessity and severe. RESULTS: 161 patients had some drug interaction. We identified 9 types of mild interactions, 23 types of interactions with close monitoring necessity, and 2 types of serious interactions. The most frequent interactions were between fluorouracil and leucovorin (32 cases) and cyclophosphamide and doxorubicin (19 cases). Serious interactions were between aspirin and pemetrexed; and leucovorin and Bactrim. CONCLUSION: In the present study, drug interactions were frequent, including serious interactions with a potential increase in morbidity and mortality. Thus, it is necessary for oncologists to draw up a therapeutic plan considering potential interactions between prescribed chemotherapy and current medications in use by patients.Associação Médica Brasileira2019-05-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000500611Revista da Associação Médica Brasileira v.65 n.5 2019reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.65.5.611info:eu-repo/semantics/openAccessMonteiro,Camila Ribeiro de ArrudaSchoueri,Jean Henri MaselliCardial,Debora TerraLinhares,Lívia de CastroTurke,Karine CorcioneSteuer,Lia VineyardMenezes,Levy Werneck de AlmeidaArgani,Igor LuizSette,ClaudiaCubero,Daniel de Iracema GomesGiglio,Auro deleng2019-05-28T00:00:00Zoai:scielo:S0104-42302019000500611Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2019-05-28T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients
title Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients
spellingShingle Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients
Monteiro,Camila Ribeiro de Arruda
Drug interactions
Antineoplastic agents/adverse effects
Medical oncology
title_short Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients
title_full Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients
title_fullStr Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients
title_full_unstemmed Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients
title_sort Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients
author Monteiro,Camila Ribeiro de Arruda
author_facet Monteiro,Camila Ribeiro de Arruda
Schoueri,Jean Henri Maselli
Cardial,Debora Terra
Linhares,Lívia de Castro
Turke,Karine Corcione
Steuer,Lia Vineyard
Menezes,Levy Werneck de Almeida
Argani,Igor Luiz
Sette,Claudia
Cubero,Daniel de Iracema Gomes
Giglio,Auro del
author_role author
author2 Schoueri,Jean Henri Maselli
Cardial,Debora Terra
Linhares,Lívia de Castro
Turke,Karine Corcione
Steuer,Lia Vineyard
Menezes,Levy Werneck de Almeida
Argani,Igor Luiz
Sette,Claudia
Cubero,Daniel de Iracema Gomes
Giglio,Auro del
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Monteiro,Camila Ribeiro de Arruda
Schoueri,Jean Henri Maselli
Cardial,Debora Terra
Linhares,Lívia de Castro
Turke,Karine Corcione
Steuer,Lia Vineyard
Menezes,Levy Werneck de Almeida
Argani,Igor Luiz
Sette,Claudia
Cubero,Daniel de Iracema Gomes
Giglio,Auro del
dc.subject.por.fl_str_mv Drug interactions
Antineoplastic agents/adverse effects
Medical oncology
topic Drug interactions
Antineoplastic agents/adverse effects
Medical oncology
description SUMMARY INTRODUCTION: Drug interaction is an important cause of global morbidity. It is of particular importance in cancer patients since they are often in use of polypharmacy, related to interactions between the drugs and the chemotherapeutics used. OBJECTIVE: To evaluate the drug interaction between chemotherapy and other drugs in cancer patients. METHODS: a cross-sectional study carried out in the outpatient oncology department of a public tertiary hospital. Two hundred thirty-five patients were included, and the drugs they were using were identified. Using the MedScape and Epocrates database, we evaluated the interactions between medications and chemotherapy by defining their frequency and dividing their severity from interaction into mild, close monitoring necessity and severe. RESULTS: 161 patients had some drug interaction. We identified 9 types of mild interactions, 23 types of interactions with close monitoring necessity, and 2 types of serious interactions. The most frequent interactions were between fluorouracil and leucovorin (32 cases) and cyclophosphamide and doxorubicin (19 cases). Serious interactions were between aspirin and pemetrexed; and leucovorin and Bactrim. CONCLUSION: In the present study, drug interactions were frequent, including serious interactions with a potential increase in morbidity and mortality. Thus, it is necessary for oncologists to draw up a therapeutic plan considering potential interactions between prescribed chemotherapy and current medications in use by patients.
publishDate 2019
dc.date.none.fl_str_mv 2019-05-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000500611
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000500611
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1806-9282.65.5.611
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.65 n.5 2019
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212834186625024